FORM 13-501F2 CLASS 2 REPORTING ISSUERS – PARTICIPATION FEE

MANAGEMENT CERTIFICATION

I, <u>GREENSLADE</u>, <u>Denby</u>, an officer of the reporting issuer noted below have examined this Form 13-50 1F2 (the **Form**) being submitted hereunder to the Alberta Securities Commission and certify that to my k nowledge, having exercised reasonable diligence, the information provided in the Form is complete and a ccurate.

(s) GREENSLADE, Denby 17 Nov 2023

Name: GREENSLADE, Denby Date:

Title: Corporate Secretary, Interim CFO, Director

Reporting Issuer Name: AREV Life Sciences Global Corp.(Formerly AREV NanoTec Brands Inc.) / AREV Life Sciences Global Corp. (Formerly AREV NanoTec Brands Inc.) (000007796)

End date of previous financial year: 31 Dec 2022

Financial Statement Values:

(Use stated values from the audited financial statements of the reporting issuer as of the end of its previous financial year)

Retained earnings or deficit \$-17,789,528.00 (A)

Contributed surplus \$ 0.00 (B)

Share capital or owners' equity, options, warrants and preferred shares \$13,667,581.00 (C) (whether such shares are classified as debt or equity for financial reporting purposes)

Non-current borrowings (including the current portion) \$1,179,484.00 (D)

Finance leases (including the current portion) \$ 0.00 (E)

Non-controlling interest	\$ 0.00 (F)
Items classified on the statement of financial position as non-current liabilities (and not otherwise listed above)	\$ 0.00 (G)
Any other item forming part of equity and not set out specifically above	\$ 3,195,092.00 (H)
Capitalization for the previous financial year (Add items (A) through (H))	\$ 252,629.00
Participation Fee	\$ 400.00
Late Fee, if applicable	\$ N/A
Total Fee Payable (Participation Fee plus Late Fee)	\$ 400.00